Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 32

recruiting
3 987
countries
28
conditions
2 109

690 trials match your criteria

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib

Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Vixarelimab

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:DC-806

Sjogren's syndrome

Not recruiting

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:VIB1116

Arthralgia

Not recruiting

Study on the Effects and Safety of ODM-111 and Paracetamol for Chronic Knee Pain in Osteoarthritis Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.